Temel İstatistikler
| CIK | 1854270 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Senti Biosciences Holdings, Inc.
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| May 26, 2026 |
[FORM OF SENIOR SECURED CONVERTIBLE NOTE] [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXCHANGEABLE OR CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 SENTI BIOSCIENCES HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 42-1912154 (State or other jurisdiction of incorporation) (Comm |
|
| May 14, 2026 |
Exhibit 99.2 Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the str |
|
| May 14, 2026 |
[SIGNATURES APPEAR ON FOLLOWING PAGES] FIRST AMENDMENT TO LANDLORD’S CONSENT TO SUBLEASE THIS FIRST AMENDMENT TO LANDLORD’S CONSENT TO SUBLEASE (this “Consent Amendment”) is dated as of September 1, 2025, and is entered into by and among 1430 SOUTH LOOP OWNER, LLC, a Delaware limited liability company (“Landlord”), SENTI BIOSCIENCES, INC. |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 SENTI BIOSCIENCES HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 42-1912154 (State or other jurisdiction of incorporation) (Comm |
|
| May 14, 2026 |
September 1, 2025 Senti Biosciences, Inc. Two Corporate Drive South San Francisco, CA 94080 Attention: Rob Cutler Re: Sublease Amendment and GeneFab Work Dear Rob: This letter (this “Letter Agreement”) is being delivered to you in accordance with that certain First Amendment to Sublease Agreement dated September 1, 2025 (the “Sublease Amendment”) entered into by and between Senti Biosciences, Inc. |
|
| May 14, 2026 |
Exhibit 99.1 Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Continued operat |
|
| May 14, 2026 |
FIRST AMENDMENT TO SUBLEASE AGREEMENT FIRST AMENDMENT TO SUBLEASE AGREEMENT THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (this “Agreement”) dated as of September 1, 2025 (the “Effective Date”), made by and between SENTI BIOSCIENCES, INC. |
|
| May 14, 2026 |
FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (“First Amendment”) is entered into as of September 1, 2025 (the “First Amendment Effective Date”), by and between 1430 SOUTH LOOP OWNER, LLC, a Delaware limited liability company (“Landlord”) and SENTI BIOSCIENCES, INC. |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Senti Biosc |
|
| May 8, 2026 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001- |
|
| May 1, 2026 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2026, is entered into by and among Senti Biosciences, Inc. |
|
| May 1, 2026 |
VOTING AGREEMENT VOTING AGREEMENT, dated as of [●], 2026 (this "Agreement"), by and between Senti Biosciences, Inc. |
|
| May 1, 2026 |
[FORM OF SENIOR SECURED CONVERTIBLE NOTE] [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXCHANGEABLE OR CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| May 1, 2026 |
SENTI BIOSCIENCES HOLDINGS, INC. Up to $17,500,000 Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-285985 Prospectus Supplement No. 1 (To Prospectus Supplement and Prospectus dated March 31, 2025) SENTI BIOSCIENCES HOLDINGS, INC. Up to $17,500,000 Common Stock This Prospectus Supplement No. 1 (this “Supplement No. 1”) to the Prospectus Supplement supplements and amends the Prospectus Supplement dated March 31, 2025 (the “ATM |
|
| May 1, 2026 |
SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement“), dated as of April 27 , 2026, by and among Senti Holdings, Inc. |
|
| May 1, 2026 |
GUARANTEE (this “Guarantee”), dated as of [], 2026, made by each of the undersigned (each a “Guarantor”, and collectively, the “Guarantors”), in favor of the Secured Parties (as defined below) in connection with the Securities Purchase Agreement, the Notes and each other Transaction Document referenced below. |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 SENTI BIOSCIENCES HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 42-1912154 (State or other jurisdiction of incorporation) (Co |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4044 |
|
| April 24, 2026 |
Amended and Restated Designation Agreement April 24, 2026 EX-10.2 Exhibit 10.2 Amended and Restated Designation Agreement April 24, 2026 Senti Biosciences Holdings, Inc. Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 New Enterprises Associates 15, L.P. 1954 Greenspring Drive, Suite 600, Timonium, MD 20193 Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to (i) that certain Securities Pur |
|
| April 24, 2026 |
ASSIGNMENT AND ASSUMPTION AGREEMENT EX-10.3 Exhibit 10.3 ASSIGNMENT AND ASSUMPTION AGREEMENT This ASSIGNMENT AND ASSUMPTION AGREEMENT (the “Agreement”) is made as of April 24, 2026, by and between Senti Biosciences, Inc., a Delaware corporation (“Assignor”) and Senti Biosciences Holdings, Inc., a Delaware corporation (“Assignee”). RECITALS WHEREAS, pursuant to the Agreement and Plan of Merger, dated as the date hereof (the “Merger A |
|
| April 24, 2026 |
EX-10.4 Exhibit 10.4 SENTI BIOSCIENCES HOLDINGS, INC. AMENDED AND RESTATED 2016 STOCK INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 24, 2026 APPROVED BY THE STOCKHOLDERS: APRIL 24, 2026 1. Purpose. The purpose of this plan (the “Plan”) is to secure for Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock own |
|
| April 24, 2026 |
EX-10.6 Exhibit 10.6 SENTI BIOSCIENCES HOLDINGS, INC. AMENDED AND RESTATED 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 24, 2026 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 5 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHE |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 S-8 POS As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 SENTI BIOSCIENCES HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 42-1912154 (State or other jurisdiction of incorporation) (Co |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 POS AM As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
SENTI BIOSCIENCES HOLDINGS, INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN EX-10.5 Exhibit 10.5 SENTI BIOSCIENCES HOLDINGS, INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such pe |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 POS AM As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 S-8 As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENTI BIOSCIENCES HOLDINGS, INC. Pursuant to Sections 242, 245 and 228 of the General General Corporation Law of the State of Delaware * * * * * Senti Biosciences Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Cor |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 S-8 POS As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 POS AM As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
EX-10.7 Exhibit 10.7 Senti Biosciences Holdings, Inc. Amended and Restated 2022 Employee Stock Purchase Plan ADOPTED BY THE BOARD OF DIRECTORS: April 24, 2026 APPROVED BY THE STOCKHOLDERS: April 24, 2026 1. GENERAL; PURPOSE. a. The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common St |
|
| April 24, 2026 |
AMENDED AND RESTATED BYLAWS OF SENTI BIOSCIENCES, INC. (A DELAWARE CORPORATION) EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF SENTI BIOSCIENCES, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 1.1 Registered Office 1 1.2 Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Location 1 2.2 Timing 1 2.3 Notice of Meeting 1 2.4 Stockholders’ Records 1 2.5 Special Meetings 2 2.6 Notice of Meeting 2 2.7 Business Transacted at Special Meeting 2 2.8 Quorum |
|
| April 24, 2026 |
EX-3.3 Exhibit 3.3 CERTIFICATE OF MERGER OF SENTI BIOSCIENCES MERGER SUB, INC. (a Delaware corporation) WITH AND INTO SENTI BIOSCIENCES, INC. (a Delaware corporation) Pursuant to Section 251 of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned corporation does hereby certify the following information in connection with the merger (the “Merger”) of Senti Biosciences |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 POS AM As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
EX-4.2 Exhibit 4.2 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences Holdings, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Current Report on Form 8-K (the “8-K”) as specified in our Amended and Restated Certificate of Incorporation (as amended and/or restated from time to time, the “Chart |
|
| April 24, 2026 |
Amended and Restated Designation Agreement April 24, 2026 EX-10.1 Exhibit 10.1 Amended and Restated Designation Agreement April 24, 2026 Senti Biosciences Holdings, Inc. Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Celadon Partners SPV 24 PO Box 500 71 Fort Street Grand Cayman, KY1-1106 Cayman Islands Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to (i) that certain Securities Purch |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 S-8 POS As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
EX-4.1 Exhibit 4.1 SPECIMEN COMMON STOCK CERTIFICATE NUMBER C–[ ] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] SENTI BIOSCIENCES HOLDINGS, INC. COMMON STOCK THIS CERTIFIES THAT [ ] is the owner of fully paid and non-assessable shares of common stock, par value US $0.0001 per share, of Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”), subject to the Company’s cert |
|
| April 24, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Senti Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share, under Amended and Restated 2022 Employee Stock Purchase Plan Other |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 S-8 POS As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (the “Agreement”), entered into as of April 24, 2026, by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”), Senti Biosciences Holdings, Inc., a Delaware corporation (“New Parent”) and a direct, wholly owned subsidiary of the Company, and Senti Biosciences Merger Sub, Inc., a Delaware corporati |
|
| April 24, 2026 |
AMENDED AND RESTATED SENTI BIOSCIENCES HOLDINGS, INC. (the “Corporation”) ARTICLE I EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SENTI BIOSCIENCES HOLDINGS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Corporation’s Board of Directors (th |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Senti Bioscience |
|
| March 27, 2026 |
Exhibit 99.1 Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update South San Francisco, Calif., March 27, 2026 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| December 9, 2025 |
ex992 NASDAQ: SNTI | sentibio.com SENTI-202-101 Promising Results in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Ongoing Phase 1 Trial (SENTI-202-101) December 9, 2025 Conference Call and Webcast Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Li |
|
| December 9, 2025 |
Exhibit 99.1 Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile •ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50 |
|
| December 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40440 Senti |
|
| November 13, 2025 |
Exhibit 99.1 Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December South San Francisco, Calif., November 13, 2025 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developi |
|
| August 7, 2025 |
Exhibit 99.1 Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 South San Francisco, Calif., August 7, 2025 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its prop |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40440 Senti Bios |
|
| July 18, 2025 |
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors Exhibit 99.1 Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has a |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 30, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
Exhibit 99.1 Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients ex |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Senti Biosc |
|
| May 6, 2025 |
Consulting Agreement by and between the Company and Yvonne Li, effective as of February 5, 2025. Exhibit 10.1 EXHIBIT A Amended and Restated SOW #2 Under Consulting Agreement Original Effective Date: February 4, 2025 A. Project: Consultant will render such services as Senti may from time to time on an ad-hoc basis request, assist the Company with its ongoing financial and audit matters at the direction of the Company’s CEO and CFO, as applicable. B. Schedule Of Work: This SOW will terminate o |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 6, 2025 |
Exhibit 99.1 Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patie |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 30, 2025 |
*# )())( (*' ) (#- # $"" (( $# ,( # )$# $'" "2C<$?6 ##*!'%$')%*'(*#))$() $# $' 5$) (*' ) ( - # )$ @CE967:D42=J62C6?565646>36C $' )'#( ) $#'%$')%*'(*#))$() $# $' 5$) (*' ) (- # )$ @CE96BF2CE6C=JA6C:@57C@>1111111E@1111111 @>>:DD:@?:=6#F>36C 999999 |
|
| April 28, 2025 |
NASDAQ: SNTI | sentibio.com SENTI-202: Positive Preliminary Results in the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML in Ongoing Phase 1 Trial (SENTI-202-101) April 28, 2025 Conference Call and Webcast Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securit |
|
| April 28, 2025 |
Exhibit 99.2 Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and prelimina |
|
| April 28, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (April 28, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| March 31, 2025 |
SENTI BIOSCIENCES, INC. Up to $17,500,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-285985 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 20, 2025) SENTI BIOSCIENCES, INC. Up to $17,500,000 Common Stock We have entered into a sales agreement, dated March 20, 2025, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock offered by this prospect |
|
| March 27, 2025 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 March 27, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 File No. 333-285985 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| March 27, 2025 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 March 27, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 File No. 333-285983 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| March 26, 2025 |
March 26, 2025 Timothy Lu Chief Executive Officer Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 Filed March 21, 2025 File No. 333-285983 Dear Timothy Lu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding req |
|
| March 26, 2025 |
March 26, 2025 Timothy Lu Chief Executive Officer Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 Filed March 21, 2025 File No. 333-285985 Dear Timothy Lu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding req |
|
| March 24, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT Exhibit 1.2 SENTI BIOSCIENCES, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT March 20, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Senti Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance a |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Senti Biosciences, Inc. |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) SENTI BIOSCIENCES, INC. |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS(1) Exhibit 4.3 SENTI BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS(1) Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cert |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS(1) Exhibit 4.4 SENTI BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS(1) Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| March 21, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 21, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT THIS AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is made as of December 10, 2024 (the “Effective Date”) by and between GeneFab, LLC, a Delaware limited company (“Provider”), with offices at 1430 Harbor Bay Parkway, Alameda, CA 94502, and Senti Biosciences, Inc. |
|
| March 20, 2025 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Annual Report on Form 10-K (the “Annual Report” or “Form 10-K”) as specified in our Second Amended and Restated Certificate of Incorporation (as amended and/or restated from time to |
|
| March 20, 2025 |
AMENDMENT NO. 1 TO OPTION AGREEMENT This AMENDMENT NO. 1 TO OPTION AGREEMENT (this “Amendment”) is made and entered into as of December 10, 2024 by and between Senti Biosciences, Inc., a Delaware corporation (the “Company”), and Celadon Partners SPV XVI, a Cayman Islands limited liability company (the “Holder”). Unless otherwise specifically defined herein, all capitalized terms used but not defin |
|
| March 20, 2025 |
SENTI BIOSCIENCES, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Senti Biosciences, Inc. and its subsidiaries, if any (collectively, the “Company”), regarding trading in certain securities, including the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Poli |
|
| March 20, 2025 |
Form of Performance Stock Unit Award Agreement. SENTI BIOSCIENCES INC. PSU AWARD GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) Senti Biosciences Inc. (the “Company”) has awarded to you (the “Participant”) the number of performance stock units specified and on the terms set forth below in consideration of your services (the “PSU Award”). Your PSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2022 Equity |
|
| March 20, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights – Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47. |
|
| March 20, 2025 |
AMENDMENT NO. 1 TO FRAMEWORK AGREEMENT This AMENDMENT NO. 1 TO FRAMEWORK AGREEMENT (this “Amendment”) is made and entered into as of December 10, 2024 by and among Senti Biosciences, Inc., a Delaware corporation (“Seller”), Valere Bio, Inc., a Delaware corporation (“TopCo”), and GeneFab, LLC, a Delaware limited liability company (“Purchaser”). Unless otherwise specifically defined herein, all capi |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 10, 2025 (March 6, 2025) Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) |
|
| March 10, 2025 |
SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.3 SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Senti Biosciences Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Compa |
|
| March 10, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 10.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| March 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2025 (March 6, 2025) Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) ( |
|
| March 7, 2025 |
2022 Inducement Plan and forms of award agreements thereunder Exhibit 99.3 SENTI BIOSCIENCES, INC. Amended and Restated 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 7, 2025 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 5 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS |
|
| March 7, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 99.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| March 7, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 10.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No. |
|
| February 25, 2025 |
Senti Bio Strengthens Leadership Team with Strategic Hires – Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (February 23, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commis |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 31, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commiss |
|
| January 27, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| January 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 6, 2025 |
Exhibit 99.1 Senti Bio Announces Additional $11.5 Million of Financing – Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., January 6, 2025 – Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stag |
|
| December 16, 2024 |
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics – Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN FRANCISCO, Calif. |
|
| December 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| December 4, 2024 |
SC 13D/A 1 nea1518913.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / SENTI BIOSCIENCES, INC. - SCHEDULE 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Senti Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 81726A209 (CUSIP Number) Stephanie Brecher |
|
| December 3, 2024 |
SENTI-202 Initial Clinical Data December 2024 Exhibit 99.1 SENTI-202 Initial Clinical Data December 2024 Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical facts and are considered forward-loo |
|
| December 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 2, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REG |
|
| December 2, 2024 |
Exhibit 3.1 SENTI BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW SENTI BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify tha |
|
| December 2, 2024 |
Exhibit 10.4 Execution Version Designation Agreement December 2, 2024 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 New Enterprises Associates 15, L.P. 1954 Greenspring Drive, Suite 600, Timonium, MD 20193 Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to that certain Securities Purchase Agreement, dated as of the date hereof, |
|
| December 2, 2024 |
Exhibit 10.3 Execution Version Designation Agreement December 2, 2024 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Celadon Partners SPV 24 PO Box 500 71 Fort Street Grand Cayman, KY1-1106 Cayman Islands Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to that certain Securities Purchase Agreement, dated as of the date hereof, by |
|
| December 2, 2024 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 2, 2024, is entered into by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). C |
|
| December 2, 2024 |
Exhibit 99.1 Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML – 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 2, 2024 Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 2, 2024 |
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing Exhibit 99.2 Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing SOUTH SAN FRANCISCO, Calif., December 2, 2024 – Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purch |
|
| December 2, 2024 |
Senti Bio Appoints Fran Schulz to Board of Directors Exhibit 99.1 Senti Bio Appoints Fran Schulz to Board of Directors – Biotechnology industry executive with a proven track record of advising management teams on corporate and financial strategy for more than 30 years – SOUTH SAN FRANCISCO, Calif., December 2, 2024 - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generati |
|
| December 2, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 2, 2024, by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are execut |
|
| November 14, 2024 |
Therapeutics, Inc., dated as of September 23, 2024. Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. STORAGE LICENSE AGREEMENT THIS STORAGE LICENSE AGREEMENT (the “License”) entered into as of September 23, |
|
| November 14, 2024 |
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights – Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| November 14, 2024 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE Two Corporate Drive, First Floor South San Francisco, CA This Sublease (“Sublease”), dated Septe |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 (October 22, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorp |
|
| September 27, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 (September 23, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of in |
|
| August 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Sen |
|
| August 13, 2024 |
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights – Dose Finding Ongoing in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML – – Commencement of $8 Million Grant Award from CIRM for the Clinical Development of SENTI-202 – SOUTH SAN FRANCISCO, Calif. |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
Sublease Agreement by and between the Company and GeneFab Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 7th day of May |
|
| August 13, 2024 |
Consulting Agreement by and between the Company and Yvonne Li, Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SENTI BIOSCIENCES, INC. CONSULTING AGREEMENT Effective Date: May 3, 2024 This Consulting Agreement (the “ |
|
| August 13, 2024 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SENTI BIOSCIENCES, INC. AMENDED AND RESTATED CONSULTING AGREEMENT Effective Date: May 4, 2024 This Amende |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| July 17, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENTI BIOSCIENCES, INC. Senti Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the Board of Directors of the Corporation has duly adopted resolutions |
|
| July 17, 2024 |
Exhibit 4.1 SPECIMEN COMMON STOCK CERTIFICATE NUMBER C–[ ] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 81726A 209 SENTI BIOSCIENCES, INC. COMMON STOCK THIS CERTIFIES THAT [ ] is the owner of fully paid and non-assessable shares of common stock, par value US $0.0001 per share, of Senti Biosciences, Inc., a Delaware corporation (the “Company”), subject to the Company’s certificate of incorporat |
|
| July 16, 2024 |
Exhibit 10.1 AMENDED AND RESTATED ChEF PURCHASE AGREEMENT This AMENDED AND RESTATED ChEF PURCHASE AGREEMENT is made and entered into as of July 16, 2024 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Senti Biosciences, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, on August 31, 2022 |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENTI BIOSCIENCES, INC. Senti Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the Board of Directors of the Corporation has duly adopted resolutions |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 (July 10, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporatio |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Senti Bioscience |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 (May 14, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Se |
|
| May 9, 2024 |
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights – First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 (April 26, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4044 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 (April 23, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporat |
|
| March 21, 2024 |
Senti Biosciences, Inc. Compensation Recovery Policy Exhibit 97 SENTI BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY Senti Biosciences, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance |
|
| March 21, 2024 |
iences, Inc., and Celest Therapeutics (Shanghai) Co. Exhibit 10.41 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND OPTION AGREEMENT This Collaboration and Option Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of November 6, 2023 (t |
|
| March 21, 2024 |
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights – IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U. |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| February 6, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2024 |
As filed with the Securities and Exchange Commission on January 10, 2024 As filed with the Securities and Exchange Commission on January 10, 2024 Registration No. |
|
| January 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| January 5, 2024 |
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program – Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 – SOUTH SAN FRANCISCO, Calif. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| December 22, 2023 |
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia – First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells – SOUTH SAN FRANCISCO, Calif. |
|
| November 14, 2023 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (t |
|
| November 14, 2023 |
Sublease Agreement by and between Senti Biosciences, Inc. and GeneFab, LLC dated August 7, 2023. Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 7th day of Aug |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 14, 2023 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SELLER ECONOMIC SHARE AGREEMENT This Seller Economic Share Agreement (this “Agreement”) is entered into a |
|
| November 14, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. [***] FRAMEWORK AGREEMENT by and among SENTI BIOSCIENCES, INC., VALERE BIO, INC. and GENEFAB, LLC DATED A |
|
| November 13, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 PROSPECTUS SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus relates to the issuance by us of up to 2,000,000 shares of our common stock, par value $0.0001 per share (“Senti Common Shares”) that may be issued as Contingency Consideration from time to time upon achievement of certain stock price thresholds (the “Ea |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates – IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – – Cash and receivables from GeneFab transaction expected to fund operations into Q4 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| November 13, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 PROSPECTUS SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 8,727,049 shares of our common stock, par value $0.0001 per share (“Senti Common Shares”) that have been or |
|
| November 6, 2023 |
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China – Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANCISCO, Calif. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
Option Agreement by and between Senti Biosciences, Inc. and GeneFab, LLC, dated August 7, 2023 Exhibit 10.8 Execution Version Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Au |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2023 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 10 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 11 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 11, 2023 |
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates – GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 – – Cash, cash equivalents, and short-term investments of $59. |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 12 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Sen |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 9 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners – Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated to extend Senti Bio’s cash runway into Q4 2024 – – Partnership with GeneFab will support manufacturing of Senti’s oncology programs, including SENTI-202, which remains on track for IND in 2H 2023 – – Dr. |
|
| August 10, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 8 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| August 10, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 10 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| June 23, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 7 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 9 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| May 9, 2023 |
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates – New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform can work in T cells, AAVs, and iPSCs – – Cash, cash equivalents, and short-term investments of $76. |
|
| May 9, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 8 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Se |
|
| May 9, 2023 |
Employee Offer Letter by and between Kanya Rajangam and Senti Biosciences, Inc., dated May 10, 2022. Exhibit 10.1 May 10, 2022 Kanya Rajangam VIA EMAIL Re: Offer of Employment Dear Kanya: Senti Biosciences, Inc. (the “Company”) is pleased to offer you employment as the Company’s Chief Medical & Development Officer (“CMDO”) on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Commencement of Employment. Your employment with the Company will commence on July 5, 2022 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock 424B3 1 a20230509424b3333-267390xs.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 6 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from ti |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 1, 2023 |
2022 Annual Report To our Stockholders: When I met Philip Lee, our Chief Technology Officer and co-founder, over 20 years ago, we didn’t know it would be the beginning of a connection that would bring Senti Biosciences into existence. |
|
| April 28, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 5 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 7 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| March 23, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 6 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| March 23, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 4 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| March 22, 2023 |
Scientific Advisory Board Agreement between Senti Biosciences, Inc. and James Collins. Exhibit 10.34 SENTI BIOSCIENCES, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Agreement”) is made and entered into as of May 14, 2021 (the “Effective Date”), by and between SENTI BIOSCIENCES, INC., a Delaware corporation (the “Company”), and DR. JAMES COLLINS an individual with an email address at [email protected] (the “Advisor”). The Company and the Advisor |
|
| March 22, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| March 22, 2023 |
Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT SENTI BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL. RESEARCH AND DEVELOPMENT AND LABORATORY LEASE AGREEMENT BETWEEN 1430 HARBOR BAY PKWY LLC AS LANDLORD AND SENTI BIOSCIENCES, INC. AS TENANT DATED JUNE 3 , 2021 1 TABLE OF |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2023 |
Side Letter between BlueRock Therapeutics, LP and Senti Biosciences, Inc., dated February 3, 2023. Exhibit 10.33 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. February 3, 2023 Senti Biosciences, Inc. 2 Corporate Drive South San Francisco, CA 94080 Attn: Chief Exe |
|
| March 22, 2023 |
Exhibit 10.32 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN SPARK THERAPEUTICS, INC. AND |
|
| March 22, 2023 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Annual Report on Form 10-K (the “Annual Report” or “Form 10-K”) as specified in our Second Amended and Restated Certification of Incorporation (the “Charter”) and our Amended and Res |
|
| March 22, 2023 |
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - - Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at American Association for Cancer Research (AACR) Annual Meeting in April 2023 - - Cash, cash equivalents, and short-term investments of $98. |
|
| February 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| February 16, 2023 |
As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No. |
|
| February 14, 2023 |
SNTI / Senti Biosciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G 1 snti13gdec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Senti Biosciences Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81726A100 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursu |
|
| February 14, 2023 |
SNTI / Senti Biosciences Inc. / Sculptor Capital LP - SC 13G/A Passive Investment SC 13G/A 1 d405260dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SENTI BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2023 |
SNTI / Senti Biosciences Inc. / BAYER HEALTHCARE LLC - SC 13G Passive Investment SC 13G 1 tm236386d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Senti Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 10, 2023 |
SNTI / Senti Biosciences Inc. / Woodline Partners LP - SENTI BIOSCIENCES, INC. Passive Investment SC 13G/A 1 p23-0152sc13ga.htm SENTI BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Senti Biosciences, Inc. (f/k/a Dynamics Special Purpose Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of event w |
|
| February 9, 2023 |
SNTI / Senti Biosciences Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment SC 13G/A 1 SentiBiosciencesSNTI.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* Senti Biosciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 81726A100 - (CUSIP Number) December 30, 2022 - (Date Of Event which Requires Filing of this Statement) Check the appr |
|
| February 8, 2023 |
EX-99.1 2 d443944dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| February 8, 2023 |
SNTI / Senti Biosciences Inc. / Lonsdale Joe - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Senti Biosciences, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 81726A100 (CUSIP Number) June 8, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 27, 2023 |
™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Engineering the Future of Cell and Gene Therapies 1 January 2023 JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. |
|
| January 27, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 5 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| January 27, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 3 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| January 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| January 27, 2023 |
EX-99.1 2 a20230127ex991pressrelease.htm PRESS RELEASE Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance – R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors – – SENTI-202 |
|
| January 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
EX-99.1 2 corporatepresentation1-.htm PRESENTATION ™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Corporate Presentation 1 January 2023 JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. Statements we make in this presentation may include statements which are not historical facts and are considered |
|
| December 12, 2022 |
corporatepresentation12 D E C E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S Corporate Presentation December 2022 ™ D E C E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S 2 Disclaimer Forward Looking Statements This presentation contains forward-looking statements. |
|
| December 12, 2022 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 2 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 2 (this ?Prospectus Supplement?) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms par |
|
| December 12, 2022 |
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event – ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – – SENTI-202 is on track for IND filing in 2H 2023 – – SENTI-202 aims to more precisely target tumor cells in CD33 and/or FLT3 expressing tumors such as acute myeloid leukemia and myelodysplastic syndrome, while sparing healthy cells – – Senti Bio Investor Event to include an AML expert; in-person and webcast at 12:30 p. |
|
| December 12, 2022 |
investoreventpresentatio ™ D E C E M B E R 2 0 2 2 IN V E ST O R E V E N T | SE N T I B IO SC IE N C E S Investor Event 1 December 2022 D E C E M B E R 2 0 2 2 IN V E ST O R E V E N T | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| December 12, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 4 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 4 (this ?Prospectus Supplement?) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms part of our Regi |
|
| November 14, 2022 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock 424B3 1 senti093022424b3333-267390.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 1 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Deborah Knobelman. EX-10.3 4 a9302210qex103.htm SEVERANCE AGREEMENT BETWEEN THE COMPANY AND DEBORAH KNOBELMAN Exhibit 10.3 July 13, 2022 Deborah Knobelman, Ph.D., CFO VIA EMAIL Re: Severance & Change in Control Agreement Dear Deb: Effective as of the date first written above, this letter agreement (the “Agreement”) sets forth your rights to receive severance payments or benefits upon an involuntary termination of yo |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Tim Lu. Exhibit 10.5 July 13, 2022 Tim Lu, Ph.D., M.D., Co-founder, President and CEO VIA EMAIL Re: Severance & Change in Control Agreement Dear Tim: Effective as of the date first written above, this letter agreement (the ?Agreement?) sets forth your rights to receive severance payments or benefits upon an involuntary termination of your employment with Senti Biosciences, Inc. (the ?Company?) or its subs |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Philip Lee. EX-10.4 5 a9302210qex104.htm SEVERANCE AGREEMENT BETWEEN THE COMPANY AND PHILIP LEE Exhibit 10.4 July 13, 2022 Philip Lee, Ph.D., Co-founder and CTO VIA EMAIL Re: Severance & Change in Control Agreement Dear Philip: Effective as of the date first written above, this letter agreement (the “Agreement”) sets forth your rights to receive severance payments or benefits upon an involuntary termination o |
|
| November 10, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.1 SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Senti Biosciences Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiarie |
